Vfend (voriconazole) NDC 0049-3160

NDC codes

FDA NDC Directory

Product NDC (as listed)0049-3160Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00049-3160Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0049-3160-44	00049316044	1 BOTTLE in 1 CARTON (0049-3160-44) / 75 mL in 1 BOTTLEMarketed from Mar 28, 2003

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Vfend
Generic name (nonproprietary): voriconazole
Active ingredients: Voriconazole — 40 mg/mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Roerig
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021630
Marketing start: Mar 28, 2003
Listing expires: Dec 31, 2027
Other FDA classes: Azoles (Chemical structure)Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 2C9 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)
Identifiers: Product ID 0049-3160_cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbeaSPL ID cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbeaSPL set ID ce3ef5cf-3087-4d92-9d94-9eb8287228dbRxCUI 349434, 349435, 351209, 352218, 352219, 352220, 465355, 546624UNII JFU09I87TR
Pharmacologic class: Azole Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400049316044 followed by a unit qualifier and the quantity

Package 00049-3160-44. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 26, 2026.

Indications (excerpt from the label)

VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021630

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021630
Product	Strength	Form · route	Labeler	Product NDC
Voriconazole	Voriconazole 40 mg/mL	Powder, For suspensionOral	Mylan Pharmaceuticals Inc.	59762-0935